ANGLE Inks Supplier Agreement With AstraZeneca To Develop A Parsortix-Based Androgen Receptor Detection Assay For Use In Prostate Cancer Studies
ANGLE Inks Supplier Agreement With AstraZeneca To Develop A Parsortix-Based Androgen Receptor Detection Assay For Use In Prostate Cancer Studies
ANGLE 與阿斯利康簽署供應商協議，開發一種基於 Parsortix 的雄激素受體檢測方法，用於前列腺癌研究
Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the Company supporting clinical studies.
根據這份向ANGLE提供價值55萬英鎊的協議條款，該公司將開發一種基於CTC的增強現實檢測。分析開發將在ANGLE的英國實驗室進行，項目預計將於2025年第一季度完成。成功的開發階段將證明Parsortix系統在評估前列腺癌療法療效方面的重要性，併爲公司支持臨床研究提供長期持續業務的潛力。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。